By Gina Shaw
Innovative pharmacy benefits manager (PBM) Abarca has entered into an outcomes-based contract for the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab (Repatha) with manufacturer Amgen, the first such agreement for the drug with a stand-alone PBM.
MARCH 9, 2018